State Street SPDR S&P Pharmaceuticals ETF
XPH
73 hedge funds and large institutions have $122M invested in State Street SPDR S&P Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 11 closing their positions.
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
24% more capital invested
Capital invested by funds: $98.6M → $122M (+$23.2M)
12% more funds holding
Funds holding: 65 → 73 (+8)
5.12% more ownership
Funds ownership: 50.1% → 55.22% (+5.1%)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
36% less call options, than puts
Call options by funds: $649K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$15M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$2.86M |
| 3 |
Morgan Stanley
New York
|
+$2.74M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.95M |
| 5 |
TCA
Taconic Capital Advisors
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIA
Gladstone Institutional Advisory
Palm Beach Gardens,
Florida
|
-$2.92M |
| 2 |
Goldman Sachs
New York
|
-$2.92M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.08M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.01M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$870K |
XPH Hedge Fund Activity: Q4 2023 in Review
73 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2023, worth a combined $122M — up 24% from $98.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XPH positions and 11 closed out — a net gain of 8 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was Bank of America, adding an estimated $15M. The largest seller was Gladstone Institutional Advisory, exiting entirely with an estimated $2.92M sold.
- 73 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2023, up from 65 in Q3 2023.
- Funds reported $122M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2023, up 24% quarter-over-quarter.
- 19 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2023 and 11 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2023 was Bank of America, an estimated $15M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2023 was Gladstone Institutional Advisory, an estimated $2.92M sold.
Based on aggregated 13F filings for Q4 2023.